Brief: Clovis Oncology Says LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy Fap-2286 Now Open For Enrollment
23/06/2021 12:13
June 23 (Reuters) - Clovis Oncology Inc CLVS.O :
* CLOVIS ONCOLOGY ANNOUNCES LUMIERE CLINICAL TRIAL
EVALUATING
NOVEL PEPTIDE-TARGETED RADIONUCLIDE THERAPY FAP-2286 NOW OPEN
FOR ENROLLMENT
Source text for Eikon: ID:nBw3VxpsZa
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber